Literature DB >> 6106367

Assessment of 35972 RP (oltipraz) a new antischistosomal drug against Schistosoma haematobium, Schistosoma mansoni, and Schistosoma intercalatum.

M Gentilini, B Duflo, D Richard-Lenoble, G Brücker, M Danis, G Niel, Y Meunier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6106367

Source DB:  PubMed          Journal:  Acta Trop        ISSN： 0001-706X            Impact factor:   3.112


× No keyword cloud information.
  4 in total

Review 1.  Schistosomiasis drug therapy and treatment considerations.

Authors:  K C Shekhar
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz.

Authors:  P J O'Dwyer; C E Szarka; K S Yao; T C Halbherr; G R Pfeiffer; F Green; J M Gallo; J Brennan; H Frucht; E B Goosenberg; T C Hamilton; S Litwin; A M Balshem; P F Engstrom; M L Clapper
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

3.  Clinical pharmacology studies of oltipraz--a potential chemopreventive agent.

Authors:  N V Dimitrov; J L Bennett; J McMillan; M Perloff; C M Leece; W Malone
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

4.  PZQ Therapy: How Close are we in the Development of Effective Alternative Anti-schistosomal Drugs?

Authors:  Raphael Taiwo Aruleba; Tayo Alex Adekiya; Babatunji Emmanuel Oyinloye; Priscilla Masamba; Londiwe Simphiwe Mbatha; Ashley Pretorius; Abidemi Paul Kappo
Journal:  Infect Disord Drug Targets       Date:  2019
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.